From major journals, first or last author from the Institute for Cancer Research
Kempkes RWM, Nikolaou C, Nabhan M, Saidu NEB(2024) IUIS 2023: yEFIS workshop on career development and code-switching Eur J Immunol, e2451155(in press) DOI 10.1002/eji.202451155, PubMed 38676471
Fleischer T, Haugen MH, Ankill J, Silwal-Pandit L, Børresen-Dale AL, Hedenfalk I, Hatschek T, Tost J, Engebraaten O, Kristensen VN(2024) An integrated omics approach highlights how epigenetic events can explain and predict response to neoadjuvant chemotherapy and bevacizumab in breast cancer Mol Oncol(in press) DOI 10.1002/1878-0261.13656, PubMed 38671580
Martin KE, Hammer Q, Perica K, Sadelain M, Malmberg KJ(2024) Engineering immune-evasive allogeneic cellular immunotherapies Nat Rev Immunol(in press) DOI 10.1038/s41577-024-01022-8, PubMed 38658708
Stålberg SM, Silwal-Pandit L, Bastani NE, Nebdal DJH, Lingjærde OC, Skålhegg BS, Kure EH(2024) Preoperative profiles of plasma amino acids and derivatives distinguish periampullary cancer and benign disease BMC Cancer, 24(1), 555 DOI 10.1186/s12885-024-12320-8, PubMed 38702616
Edsjö A, Russnes HG, Lehtiö J, Tamborero D, Hovig E, Stenzinger A, Rosenquist R, PCM4EU consortium(2024) High-throughput molecular assays for inclusion in personalised oncology trials - State-of-the-art and beyond J Intern Med(in press) DOI 10.1111/joim.13785, PubMed 38698538
Esperon P, Neffa F, Pavicic W, Spirandelli F, Alvarez K, Mullins MJ, Rossi BM, Góngora E Silva RF, Vaccaro C, Lopéz-Köstner F, Rugeles J, Valle AD, Dominguez-Valentin M(2024) A comprehensive characterization of the spectrum of MUTYH germline pathogenic variants in Latin America Fam Cancer(in press) DOI 10.1007/s10689-024-00382-3, PubMed 38687439